A Science-Based Approach To Product Development
Abon Pharmaceuticals, LLC is a specialty pharmaceutical company focused on complex generics and proprietary products across injectable, oral and other dosage forms with a high barrier to entry.
About Us
Abon specializes in developing a broad range of pharmaceutical products and integrates product quality by formulation and process design. At Abon, we emphasize using scientific methods and modern technology to improve dosage form efficiency, enable robust processing, and enhance patient compliance.
On the Spotlight
Salah Ahmed, Ph.D. awarded Distinguished Alumni at the 7th Annual College of Pharmacy and Health Sciences Gala of St John's University.
Milestones
On March 18, 2024, Abon received FDA approval of its ANDA for a generic version of Carafate® (sucralfate) Oral Suspension, 1 g/10 ml. “We are pleased to announce our approval of this complex product. We are preparing to launch it shortly,” said Salah Ahmed, CSO, President and CEO of Abon.
According to IQVIA™, U.S market annual sales for sucralfate oral suspension was estimated to be approximately $146 million.
© 2024 Abon Pharmaceuticals, LLC